Skip to main content

Day: December 3, 2019

HTG Molecular Diagnostics to Host Key Opinion Leader Meeting on the Future of Precision Medicine

TUCSON, Ariz., Dec. 03, 2019 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it will host a Key Opinion Leader (KOL) luncheon at 12:00 pm ET on Friday, December 13th in Boston, Massachusetts.The event will feature a presentation by Laura E. Benjamin, Ph.D., Founder and CEO, Oncologie, LTD, who will discuss the future of precision medicine and its potential to bring innovative new medicines to cancer patients globally. Oncologie and HTG are partnering on the development of biomarkers associated with Oncologie’s immuno-oncology pipeline. Laura E. Benjamin will be available at the conclusion of the event to answer any questions.HTG’s management team will also discuss the company’s Pharma partnership model and its...

Continue reading

CytoDyn Reports Early Results from First Patient in its Phase 1b/2 CCR5+ Metastatic Triple-Negative Breast Cancer Trial

First metastatic triple-negative breast cancer patient showed no detectable circulating tumor cells (CTC) or putative metastatic tumor cells (EMTs) in the peripheral blood. Further, a significant reduction in CCR5 expression was demonstrated on cancer-associated cells after eight weeks of treatment with leronlimabA second patient with metastatic breast cancer has been enrolled under an emergency use investigational new drugVANCOUVER, Washington, Dec. 03, 2019 (GLOBE NEWSWIRE) — CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today additional early Phase 1b/2 clinical trial results evaluating leronlimab (PRO 140) patients with CCR5+ metastatic triple-negative breast...

Continue reading

Ferrellgas Collecting Winter Clothing Items for Those in Need

OVERLAND PARK, Kan., Dec. 03, 2019 (GLOBE NEWSWIRE) — As a company that serves the propane needs of homes, businesses, and farms across the country, Ferrellgas knows a thing or two about keeping America warm. This year Ferrellgas is once again asking its customers—and all the members of the thousands of communities it serves—to help spread even more warmth throughout the area this holiday season.Giving Tuesday, celebrated each year on the Tuesday immediately following Thanksgiving, encourages individuals, groups, and organizations to make a tangible and positive impact within their respective communities. With the backdrop of this global generosity initiative, hundreds of Ferrellgas offices across the country are collecting new and gently used coats, hats, scarves, and gloves as part of its Share The Warmth campaign. This program,...

Continue reading

Atreca Announces FDA Clearance of Investigational New Drug Application for ATRC-101

First IND clearance of a clinical candidate derived from Atreca’s differentiated drug discovery platform Phase 1b clinical trial in patients with solid tumors to begin in early 2020REDWOOD CITY, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) — Atreca, Inc. (Atreca) (NASDAQ: BCEL), a biotechnology company focused on the development of novel cancer therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application. Atreca expects to initiate a first-in-human Phase 1b clinical trial of ATRC-101 in patients with solid tumors in early 2020.“The FDA’s clearance of our IND application for ATRC-101 is a significant milestone for Atreca and validates the ability...

Continue reading

Dermavant Announces First Patient Dosed in Phase 2a Clinical Trial of Topical Dual JAK/Syk Inhibitor Cerdulatinib for Vitiligo

Phase 2a clinical trial for topical cerdulatinib to enroll 30 patients with vitiligoTop-line results anticipated in second half of 2020BASEL, Switzerland and LONG BEACH, Calif., Dec. 03, 2019 (GLOBE NEWSWIRE) — Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences, today announced that the first patient has been dosed in its Phase 2a vitiligo clinical trial for topical cerdulatinib. Cerdulatinib is a dual inhibitor of the Janus kinase (JAK) and spleen tyrosine kinase (Syk) pathways, which Dermavant is evaluating as a differentiated topical treatment option for vitiligo and other inflammatory skin conditions such as atopic dermatitis.“With vitiligo affecting an estimated 65-95 million people worldwide, including approximately 2.4 million people in the U.S., I am excited to announce that the first vitiligo patient...

Continue reading

Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan

MORRIS PLAINS, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) — Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced the resubmission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval of sacituzumab govitecan for the treatment of patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for metastatic disease.“We appreciate FDA’s guidance during the resubmission period and look forward to working closely with the Agency during the BLA review,” said Dr. Behzad Aghazadeh, Executive Chairman of Immunomedics. “We are pleased to have reached this important milestone and believe that sacituzumab govitecan,...

Continue reading

Adam Fishman, Esq. to Join Barrel Energy Advisory Board

LAS VEGAS, Dec. 03, 2019 (GLOBE NEWSWIRE) — Barrel Energy Inc., (OTC Markets: BRLL) (the “Company” or “Barrel”) is pleased to announce that Adam Fishman, Esq. will join the company as Managing Director Israel and will focus on business opportunities in Israel, primarily for Military and Law Enforcement uses. Fishman holds dual U.S./Israeli citizenship. He was in-house counsel for United Airlines before immigrating to Israel in 2005, where he became V.P. of Legal Affairs and Director of Development for a corporate financial and technology consultancy. Mr. Fishman has developed significant relationships in Israeli hi-tech and innovation, security and governmental sectors. He has also served in professional leadership capacities with AIPAC and American Friends of Likud.Barrel’s Chairman, Harpreet Sangha, stated, “We are delighted to...

Continue reading

SilverCrest Announces C$80 Million Bought Deal Financing

VANCOUVER, B.C., Dec. 03, 2019 (GLOBE NEWSWIRE) — SilverCrest Metals Inc. (“SilverCrest” or the “Company”) is pleased to announce that it has entered into an agreement with a syndicate of underwriters (the “Underwriters”) led by National Bank Financial Inc., Desjardins Capital Markets and Scotiabank, pursuant to which the Underwriters have agreed to purchase, on a bought-deal basis, 11,000,000 common shares of the Company (“Shares”) at a price of C$7.28 per Share for aggregate gross proceeds to the Company of C$80,080,000 million (the “Offering”).The Underwriters have been granted an option (the “Over-Allotment Option”), exercisable in whole or in part, at any time within 30 days following the closing of the Offering, to purchase from the Company up to an additional 15% of the Shares offered under the Offering.The Company will pay...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – Endeavour Mining Corporation – Ordinary shares

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 17,202 shares.All interests and all short positions should be disclosed.Details of any open stock-settled derivative...

Continue reading

Dimensional Fund Advisors Ltd. : Form 8.3 – Centamin plc – Ordinary shares

FORM 8.3PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BYA PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”)1.         KEY INFORMATION2.         POSITIONS OF THE PERSON MAKING THE DISCLOSUREIf there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.(a)        Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)*Dimensional Fund Advisors Ltd. and / or its affiliates do not control voting discretion for 3,242,230 shares.All interests and all short positions should be disclosed.Details of any open stock-settled...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.